Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 172 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Endometriosis Clear all
Active, not recruiting Phase 2 Interventional

Glycemic Regulation as Endometriosis Adjunct Treatment

NCT06611501
View directory record Official record
Conditions
Pelvic Pain, Endometriosis
Interventions
Metformin Hydrochloride, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 4, 2026, 4:02 PM EDT
Active, not recruiting No phase listed Observational

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

NCT05739136
View directory record Official record
Conditions
Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
Interventions
Relugolix + Estradiol + Norethindrone Acetate
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

Ulipristal for Endometriosis-related Pelvic Pain

NCT02213081
View directory record Official record
Conditions
Endometriosis
Interventions
Ulipristal
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis

NCT04173169
View directory record Official record
Conditions
Infertility, Endometriosis
Interventions
Elagolix 200 MG, Placebo or SOC IVF
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Aurora, Colorado • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 4, 2026, 4:02 PM EDT
Terminated Not applicable Interventional

Fluorescence Imaging + ICG Dye for Use in the Visual Diagnosis of Endometriosis

NCT02038985
View directory record Official record
Conditions
Endometriosis
Interventions
Participants will receive ICG Dye
Other
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 4, 2026, 4:02 PM EDT
Not listed Phase 3 Interventional

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

NCT00458458
View directory record Official record
Conditions
Endometriosis, Dysmenorrhea, Dyspareunia
Interventions
Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Cabergoline for the Treatment of Chronic Pain Due to Endometriosis

NCT03928288
View directory record Official record
Conditions
Endometriosis
Interventions
Cabergoline 0.5 MG, Placebo - Cap
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 4, 2026, 4:02 PM EDT
Recruiting Phase 3 Interventional

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

NCT05862272
View directory record Official record
Conditions
Uterine Fibroids, Endometriosis
Interventions
Relugolix Combination Tablet
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
120
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial

NCT00474851
View directory record Official record
Conditions
Endometriosis
Interventions
Norethindrone acetate + estrogens, norethindrone acetate + placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 22 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2015 · Synced Sep 4, 2026, 4:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Validation and Refinement of Noninvasive Diagnostic Biomarkers for Endometriosis, The ENDOmarker Protocol

NCT03161704
View directory record Official record
Conditions
Endometriosis
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
5
States / cities
New Haven, Connecticut • Augusta, Georgia • Southfield, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 4, 2026, 4:02 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cardiovascular Disease Risk in Women With Endometriosis

NCT03746535
View directory record Official record
Conditions
Endometriosis
Interventions
Elagolix
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 4, 2026, 4:02 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Evaluation of Women With Endocrine and Reproductive-Related Conditions

NCT00001850
View directory record Official record
Conditions
Endocrine Disease, Infertility, Leiomyoma, Endometriosis, Fibroids
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Year to 85 Years
Enrollment
833 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 1 Interventional

Acupuncture for Women's Health Conditions

NCT00090389
View directory record Official record
Conditions
Ovarian Neoplasms, Endometriosis, Pelvic Pain, Uterine Neoplasms
Interventions
Chinese Acupuncture
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2008 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Not applicable Interventional

Characteristics of Patient Population With Endometriosis

NCT03002870
View directory record Official record
Conditions
Endometriosis
Interventions
Questionnaires
Other
Lead sponsor
St. Louis University
Other
Eligibility
13 Years to 55 Years · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

NCT03213457
View directory record Official record
Conditions
Endometriosis
Interventions
Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
188
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 4, 2026, 4:02 PM EDT
Active, not recruiting Phase 3 Interventional

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

NCT04333576
View directory record Official record
Conditions
Endometriosis
Interventions
Elagolix, Placebo, Combined Oral Contraceptive
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
176
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 134 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Not applicable Interventional Results available

Endometriosis Group Care

NCT05622955
View directory record Official record
Conditions
Endometriosis, Pelvic Pain
Interventions
Peer Empowered Endometriosis Pain Support (PEEPS)
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 4, 2026, 4:02 PM EDT
Withdrawn Phase 2 Interventional

SIRT-1 Antagonism for Endometrial Receptivity

NCT04184323
View directory record Official record
Conditions
Endometriosis, Uterine Diseases, Endometrial Diseases, Infertility Unexplained, Infertility; Female, Nonimplantation
Interventions
EX-527 (Selisistat), Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03654274
View directory record Official record
Conditions
Endometriosis
Interventions
Relugolix, Estradiol/norethindrone acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
60
States / cities
Andalusia, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 4, 2026, 4:02 PM EDT
Withdrawn Phase 2 Interventional

IUD and Norethindrone Acetate for Treatment of Endometriosis

NCT04948489
View directory record Official record
Conditions
Endometriosis
Interventions
norethindrone acetate (NETA), Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 24 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 4, 2026, 4:02 PM EDT
Withdrawn Phase 2 Interventional

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

NCT06834997
View directory record Official record
Conditions
Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
Interventions
Dronabinol Capsules, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Hosuton, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 4, 2026, 4:02 PM EDT
Not yet recruiting Phase 2 Interventional

Rimegepant For Endometriosis Pain

NCT07795125
View directory record Official record
Conditions
Endometriosis, Endometriosis-related Pain
Interventions
Rimegepant 75 MG, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 4, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

NCT01728454
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, Telapristone acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Tucson, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 4, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional Results available

Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb

NCT04614246
View directory record Official record
Conditions
Endometriosis
Interventions
BAY1817080, Elagolix, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 4, 2026, 4:02 PM EDT